Navigation Links
Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/6/2009

550 547 Additional paid in capital 216,831 214,467 Accumulated deficit (173,563) (151,614) Accumulated other comprehensive income 276 24 Total stockholders' equity 44,094 63,424 Total liabilities and stockholders' equity $76,983 $98,222 SAVIENT PHARMACEUTICALS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) Three Months Ended March 31, 2009 2008 Revenues: Product sales, net $1,085 $1,144 Other revenues 3 44 1,088 1,188 Cost and expenses: Cost of goods sold 491 333 Research and development 12,763 11,161 Selling, general and administrative 9,468 9,264 22,722 20,758 Operating loss (21,634) (19,570) Investment income (expense), net (202) 953 Other expense, net (113) (150) Loss before income taxes (21,949) (18,767) Income tax benefit - (1,215) Net loss $(21,949) $(17,552) Loss per common share:
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Submits Biologics License Application (BLA) for pegloticase
4. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Announces Appointment of David Gionco as Chief Financial Officer
7. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
8. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , ... July 31, 2015 , ... ... competitive market analysis and premium industry insights on the global resorcinol industry. The ... a collective study of vivid market scenarios and analysis of primary and secondary ...
(Date:7/31/2015)... ... 2015 , ... R-Biopharm is proud to announce the RIDASCREEN® ... foods, has been accepted by AOAC International as Official First Action method. The ... Products by R5 Competitive ELISA,” based on a specific monoclonal antibody to potentially ...
(Date:7/30/2015)... -- AACC welcomed thousands of medical professionals and ... & Clinical Lab Expo in Atlanta ... revolutionary advancements in clinical testing technology and research ... diagnose patients quickly and accurately and make sure ... As of Wednesday, July 29, more than 17,500 ...
(Date:7/30/2015)... Grenoble, France and Dallas, TX, USA (PRWEB) , ... ... ... manufacturer of innovative nano and microsystems, has appointed Francois Vieillard as Sales & ... & Marketing at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2
... Elaine & Kenneth Langone contribute unrestricted $200 Million Gift, ... http://www.med.nyu.edu/ ) today announced it will be renamed the ... honor of the chairman of its,board of trustees and ... in the Medical Center,s history., The announcement was ...
... Tuesday, April 22 ... Networking Reception 5:30 ... 6:30 p.m., Where: 610 ... Workshop: Capital Formation: Lost in Translation ...
... ROCHELLE, N.Y., April 16 Biotech and pharma,companies ... drug,discovery work, reports Genetic Engineering & Biotechnology News ... cost means of testing drug,candidates for toxic effects, ... issue,of GEN ( http://www.genengnews.com/articles/chitem.aspx?aid=2437 )., "Better screening ...
Cached Biology Technology:NYU Medical Center Changes Name to Honor Chairman of Board & Wife 2NYU Medical Center Changes Name to Honor Chairman of Board & Wife 3NYU Medical Center Changes Name to Honor Chairman of Board & Wife 4NYU Medical Center Changes Name to Honor Chairman of Board & Wife 5MichBio Will Host Workshop on Capital Formation Prior to April 22 Annual Meeting 2Genetic Engineering & Biotechnology News Reports on Growing Use of Cell-Based Assays 2
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... oil spills and metal contaminates in a low-impact, sustainable ... governments globally. But a group of researchers ... that can be modified to absorb oil and chemicals ... offer a cheaper and "greener" method to absorb oil ...
... Inc., a San Antonio-based early stage medical device company ... San Antonio (UTSA), was honored at the Texas Life ... Life Science Companies recognized for having the best business ... technology, biotech and pharma companies competed in the event ...
... The active ingredient in vinegar, acetic acid, can ... tuberculosis , an international team of researchers from ... mBio , the online open-access journal of the ... be used as an inexpensive and non-toxic disinfectant ...
Cached Biology News:'Greener' aerogel technology holds potential for oil and chemical clean-up 2Leto Solutions honored as 1 of top 10 best companies at 2014 Texas Life Science Forum 2Leto Solutions honored as 1 of top 10 best companies at 2014 Texas Life Science Forum 3Vinegar kills tuberculosis and other mycobacteria 2Vinegar kills tuberculosis and other mycobacteria 3
Protein 3D structure prediction, via threading. Easy to use....
... Blot Processing mini Tray (3 per ... gel staining and blot processing.Automated staining ... for proteins and nucleic acid analysis.Prepares ... and chromogenic detection.Programmable control of protocol, ...
GOAT ANTI HUMAN PARAINFLUENZA VIRUS 2+3...
... Varian Cary 50 Microplate Reader ... cost per analysis by extending ... the award-winning Cary 50 instruments. ... to 384 samples in microlitre ...
Biology Products: